ABSTRACT
A 46-year-old man with cirrhosis secondary to hepatitis C virus infection and alcohol underwent orthotopic liver transplantation, which required urgent re-grafting because of biliary sepsis from necrosis of the left liver lobe. Recovery was complicated by renal failure and nephrogenic systemic fibrosis (probably related to intravenous gadolinium exposure). He subsequently developed a malignant fibrous histiocytoma. We present this case highlighting the occurrence of two rare conditions in the same patient following liver transplantation. We believe this is the first case of its kind to be reported.
Subject(s)
Histiocytoma, Malignant Fibrous/diagnosis , Liver Transplantation/adverse effects , Nephrogenic Fibrosing Dermopathy/diagnosis , Postoperative Complications/diagnosis , Fatal Outcome , Histiocytoma, Malignant Fibrous/complications , Histiocytoma, Malignant Fibrous/therapy , Humans , Male , Middle Aged , Nephrogenic Fibrosing Dermopathy/etiology , Nephrogenic Fibrosing Dermopathy/therapy , Postoperative Complications/therapyABSTRACT
We report a case of multi-system organ failure as a result of unsuspected colchicine overdose in a patient with known gout and bulimia nervosa. The patient had initially presented with mild gastrointestinal symptoms with rapid progression to fulminant hepatic failure and multiple organ dysfunction before the causative agent was identified. The patient survived with aggressive intensive care support and ongoing medical treatment. Physicians should be aware of the risk assessment based on the ingested dose, that the clinical presentation of colchicine in toxic doses may be nonspecific with high potential for severe morbidity or death and that survival may occur despite multiple organ failure requinng aggressive support.
Subject(s)
Abdomen, Acute/chemically induced , Colchicine/poisoning , Gout Suppressants/poisoning , Multiple Organ Failure/chemically induced , Abdomen, Acute/therapy , Adult , Diagnosis, Differential , Drug Overdose , Female , Gout/drug therapy , Humans , Liver Failure, Acute/chemically induced , Multiple Organ Failure/therapy , Treatment OutcomeABSTRACT
BACKGROUND: Between 1988 and 2002, eight patients were referred to our unit from other institutions, for management of fulminant hepatic failure (FHF) complicating severe veno-occlusive disease (VOD). AIM: To review our experience with these patients. METHODS: Retrospective analysis of medical case notes. RESULTS: In 7/8 cases, a histological diagnosis of VOD was confirmed by transjugular liver biopsy or post-mortem examination. All had undergone high-dose chemotherapy. Cyclophosphamide was included in the conditioning regimen of six patients. All developed encephalopathy and four progressed to grade 3 or 4 encephalopathy. All patients died, none surviving >75 days after haematopoietic cell transplantation. Three were listed for liver transplantation: one underwent transplantation, and two died before transplantation could be performed. Two suffered significant complications of transjugular liver biopsy. One underwent transjugular intrahepatic porto-systemic venous stent (TIPS) insertion. DISCUSSION: FHF complicating severe VOD is associated with multi-organ failure, and has a very poor prognosis. Our experience and that described in published literature, questions the benefits of measures such as liver transplantation or prolonged intensive care.
Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Hepatic Veno-Occlusive Disease/complications , Liver Failure/etiology , Postoperative Complications/etiology , Adult , Fatal Outcome , Female , Hepatic Veno-Occlusive Disease/mortality , Humans , Liver Failure/mortality , Male , Middle Aged , Postoperative Complications/mortality , Retrospective StudiesABSTRACT
BACKGROUND AND AIMS: To determine response rate, side-effects and compliance in patients with chronic hepatitis C virus (HCV) infection following treatment with interferon-alpha-2b and ribavirin in a 'shared care' hospital clinic. METHODS: Data were collected prospectively on 81 patients treated with combination therapy for chronic HCV infection between 1999 and 2001. All had biochemical and virological evidence of active infection. All patients had undergone liver biopsy except haemophiliac patients. Patients infected with genotype 1 were treated for 12 months. Patients infected with genotypes 2 and 3 were treated for 6 months. Patient care was shared with the referring general practitioner. Intention to treat, end of treatment and sustained virological response (SVR) rates, side-effects and compliance were assessed. RESULTS: Eighty-one patients with chronic HCV infection were treated with combination therapy. The majority of HCV patients were genotype 1 (n = 46; 57%). There were 12 patients (15%) with cirrhosis. SVR rates were: (i) 24% for genotype 1, (ii) 58% for genotype 3 and (iii) 75% for genotype 2. SVR was achieved in three (23%) cirrhotic patients. Compliance with the treatment regimen was 98%. Seven per cent of patients were withdrawn from therapy prematurely because of side-effects. CONCLUSIONS: These 'shared care' clinic results compare well with controlled clinical trials using combination therapy for chronic HCV infection. Outcomes were poorer in genotype 1 patients and in patients with cirrhosis. Compliance with therapy was excellent because of the 'Shared Care Programme' with participation of general practitioners, psychiatrists and hepatitis C nurse practitioners in the management protocol.
